Epiloid's preclinical neurological drug testing is 5 times more predictable with our lab-grown human brain organoids.
Less than 6% of neurology drugs make it to market
Preclinical models often fail to mimic human brain function, missing key signs of toxicity or drug effectiveness
Every failed candidate can cost $0.8–1.6 billion
With Epiloid, drug development is no longer guesswork. It’s informed by human-relevant data from the start.
